Skip to main content

Advertisement

SpringerLink
Log in

Immunity, Inflammation, and Bipolar Disorder: Diagnostic and Therapeutic Implications

  • Bipolar Disorders (WH Coryell, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Bipolar disorder is now known to be associated not only with highly prevalent co-occurring psychiatric and substance use disorders but also with medical comorbidities, such as cardiovascular diseases, diabetes mellitus, obesity and thyroid dysfunction. Inflammatory disturbances repeatedly observed in bipolar disorder, can explain some of the comorbidity between bipolar disorder and medical disorder. This revised perspective of bipolar disorders should promote the development of therapeutic tools. Immuno-inflammatory dysfunction may well represent a significant component of the underlying pathophysiology of the disorder. We therefore propose to review the immuno-inflammatory hypothesis in bipolar disorder considering the co-occurence with autoimmune diseases, immunological and inflammatory markers, as well as immuno-genetic markers which could lead to personalized treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Recently published papers on the latest scientific advances on immunoinflammation in bipolar disorders have been highlighted as:• Of importance

  1. Bauer MS, Altshuler L, Evans DR, et al. Prevalence and distinct correlates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. J Affect Disord. 2005;85:301–15.

    Article  PubMed  Google Scholar 

  2. • Leboyer M, Kupfer DJ. Bipolar disorder: new perspectives in health care and prevention. J Clin Psychiatry. 2010;71(12):1689–95. An original paper with useful advices.

    Article  PubMed  Google Scholar 

  3. • Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord. 2012;141(1):1–10. A good review of comorbid diseases in bipolar disorder.

    Article  PubMed  Google Scholar 

  4. Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368–73.

    Article  PubMed  Google Scholar 

  5. Kupfer DJ. The increasing medical burden in medical disorder. JAMA. 2005;20:2528–30.

    Article  Google Scholar 

  6. Goldstein BI, Kem DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078–90.

    Article  PubMed  Google Scholar 

  7. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008;10:788–97.

    Article  PubMed  Google Scholar 

  8. Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60(2):147–56.

    Article  PubMed  Google Scholar 

  9. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–50.

    Article  PubMed  CAS  Google Scholar 

  10. Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011;23(1):40–7.

    PubMed  Google Scholar 

  11. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S–60S.

    PubMed  CAS  Google Scholar 

  12. Laaksonen D, Lakka HM, Niskanen L, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–7.

    Article  PubMed  Google Scholar 

  13. Lakka TA, Niskanen LK, Kumpusalo E, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.

    Article  PubMed  Google Scholar 

  14. Mc Intyre RS, Konarski JZ, Misener VL, et al. Bipolar disorder and diabete mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry. 2005;17(2):83–93.

    Article  Google Scholar 

  15. Salvi V, D'Ambrosio V, Rosso G, Bogetto F, Maina G. Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. Psychiatry Clin Neurosci. 2011;65:47–54.

    Article  PubMed  Google Scholar 

  16. Miller BJ, Mellor A, Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav Immun. 2013;31:82–9.

    Article  PubMed  CAS  Google Scholar 

  17. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, et al. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008;20:131–7.

    Article  PubMed  Google Scholar 

  18. Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: why the excess cardiovascular risk in bipolar disorder? 2009;11(6):475–480.

  19. Maina G, Salvi V, Vitalucci A, D’Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. J Affect Disord. 2008;110(1–2):149–55.

    Article  PubMed  Google Scholar 

  20. Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry. 2007;68(6):917–23.

    Article  PubMed  Google Scholar 

  21. Johannessen L, Strudsholm U, Foldager L, Munk-Jørgensen P. Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord. 2006;95:13–7.

    Article  PubMed  Google Scholar 

  22. Angst F, Stassenm HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow up of 34–38 years. J Affect Disord. 2002;68:167–81.

    Article  PubMed  CAS  Google Scholar 

  23. Perris C, d'Ellia G. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand. 1996;164:172–89.

    Google Scholar 

  24. Tsuang MT, Woolson RF, Fleming JA. Premature deaths in schizophrenia and affective disorders. An analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry. 1980;37(9):979–83.

    Article  PubMed  CAS  Google Scholar 

  25. • Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12(6):638–46. Good topic for autoimmunity in bipolar disorder with interesting data.

    Article  PubMed  Google Scholar 

  26. Vonk R, Van der Schot AC, Kahn RS, et al. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol Psychiatry. 2007;62(2):135–40.

    Article  PubMed  CAS  Google Scholar 

  27. Cassidy F, Ahearm E, Carroll BJ. Elevated frequency of diabete mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156(9):1417–20.

    PubMed  CAS  Google Scholar 

  28. Kupka RW, Regeer EJ. Bipolar mood disorders. Ned Tijdschr Geneeskd. 2007;151(41):2256–60.

    PubMed  CAS  Google Scholar 

  29. Severance EG, Dickerson FB, Halling M, et al. Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr Res. 2010;118(1–3):240–7.

    Article  PubMed  Google Scholar 

  30. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem. 2009;48:111–36.

    Article  PubMed  CAS  Google Scholar 

  31. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med. 2006;119(2):166.e17–28.

    Article  Google Scholar 

  32. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–86.

    Article  PubMed  CAS  Google Scholar 

  33. Pasco JA, Nicholson GC, Williams LJ, et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry. 2010;197:372–7.

    Article  PubMed  Google Scholar 

  34. Wadee AA, Kuschke RH, Wood LA, et al. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol. 2002;17(4):175–9.

    Article  PubMed  Google Scholar 

  35. Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):370–2.

    Article  PubMed  CAS  Google Scholar 

  36. Dickerson F, Stallings C, Origoni A, et al. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):952–5.

    Article  PubMed  CAS  Google Scholar 

  37. De Berardis D, Conti CM, Campanella D, Carano A, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol. 2008;21(2):319–24.

    PubMed  Google Scholar 

  38. Cunha AB, Andreazza AC, Gomes FA, Frey BN, et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258(5):300–4.

    Article  PubMed  Google Scholar 

  39. Tsai SY, Chen KP, Yang YY, et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry. 1999;45(8):989–94.

    Article  PubMed  CAS  Google Scholar 

  40. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104(1–3):91–5.

    Article  PubMed  CAS  Google Scholar 

  41. Ortiz-Dominguez A, Hernandez ME, Berlanga C, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9(6):596–602.

    Article  PubMed  CAS  Google Scholar 

  42. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90(2–3):263–7.

    Article  PubMed  Google Scholar 

  43. Rapaport MH, Guylai L, Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatr Res. 1999;33(4):335–40.

    Article  PubMed  CAS  Google Scholar 

  44. Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord. 2012;136(1–2):110–6.

    Article  PubMed  CAS  Google Scholar 

  45. Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun. 2009;23(8):1079–82.

    Article  PubMed  CAS  Google Scholar 

  46. Knijff EM, Breunis MN, Kupka RW, et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007;9(7):743–53.

    Article  PubMed  CAS  Google Scholar 

  47. Mollace V, Muscoli C, Masini E, et al. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev. 2005;57(2):217–52.

    Article  PubMed  CAS  Google Scholar 

  48. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34(4):263–71.

    PubMed  Google Scholar 

  49. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15(4):384–92.

    Article  PubMed  CAS  Google Scholar 

  50. Kapczinski F, Dias VV, Kauer-Sant'Anna M, Brietzke E, Vazquez GH, Vieta E, et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1366–71.

    Article  PubMed  CAS  Google Scholar 

  51. Berk M, Conus P, Lucas N, Hallam K, Malhi GS, Dodd S, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007;9(7):671–8.

    Article  PubMed  Google Scholar 

  52. • Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144(1–2):16–27. doi:10.1016/j.jad.2012.06.010. A recent meta-analysis to assess the role of cytokines in bipolar disorder.

    Article  PubMed  CAS  Google Scholar 

  53. Pawelec G, Barnett Y, Forsey R, et al. T cells and aging. Front Biosci. 2002;7:d1056–183.

    PubMed  CAS  Google Scholar 

  54. Czerski PM, Rybakowski F, Kapelski P, Rybakowski JK, et al. Association of tumor necrosis factor -308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology. 2008;57(1–2):88–94.

    Article  PubMed  CAS  Google Scholar 

  55. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002;20(5 Suppl 27):S1–S13.

    PubMed  CAS  Google Scholar 

  56. Hwang JP, Tsai SJ, Hong CJ, et al. Interleukin-1 beta -511C/T genetic polymorphism is associated with age of onset of geriatric depression. Neuromolecular Med. 2009;11(4):322–7.

    Article  PubMed  CAS  Google Scholar 

  57. Papiol S, Molina V, Desco M, et al. Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13). Genes Brain Behav. 2008;7(7):796–801.

    Article  PubMed  CAS  Google Scholar 

  58. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 65(4):395–407.

  59. Thorsby E, Lie BA. HLA associated genetic predisposition to autoimmune diseases: genes involved and possible mechanisms. Transpl Immunol. 2005;14(3–4):175–82.

    Article  PubMed  CAS  Google Scholar 

  60. Biederman J, Keller M, Lavori P, et al. HLA haplotype A26-B38 in affective disorders: lack of association. Biol Psychiatry. 1987;22(2):221–4.

    Article  PubMed  CAS  Google Scholar 

  61. Sorokina TT, Evsegneev RA, Levin VI, Semenov GV. Features of the distribution of HLA-antigens among patients with endogenous psychose. Zh Nevropatol Psikhiatr Im S S Korsakova. 1987;87(6):885–8.

    PubMed  CAS  Google Scholar 

  62. • Debnath M, Busson M, Jamain S, et al. The HLA-G low expressor genotype is associated with protection against bipolar disorder. Hum Immunol. 2013;74(5):593–7. Recent data for the implication of the HLAG in bipolar disorder.

    Article  PubMed  CAS  Google Scholar 

  63. Biederman J, Keller M, Lavori P, Harmatz J, Knee D, Dubey D, et al. HLA haplotype A26-B38 in affective disorders: lack of association. Biol Psychiatry. 1987;22(2):221–4.

    Article  PubMed  CAS  Google Scholar 

  64. Bozikas VP, Anagnostouli MC, Petrikis P, et al. Familial bipolar disorder and multiple sclerosis: a three-generation HLA family study. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(5):835–9.

    Article  PubMed  Google Scholar 

  65. Kaminsky Z, Tochigi M, Jia P, et al. A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder. Mol Psychiatry. 2012;17(7):728–40. doi:10.1038/mp.2011.64.

    Article  PubMed  CAS  Google Scholar 

  66. Griffiths DJ. Endogenous retroviruses in the human genome sequence. Genome Biol. 2001;2(6):reviews 1017.

    Article  CAS  Google Scholar 

  67. Venter A. New protein blocks HIV. Trends Microbiol. 2001;9(3):110.

    Article  PubMed  CAS  Google Scholar 

  68. Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein–Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity. 2001;15(4):579–89.

    Article  PubMed  CAS  Google Scholar 

  69. • Hamdani N, Daban-Huard C, Lajnef M, et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord. 2013;148(2–3):444–8. Recent data presenting the link between infectious agents and bipolar disorder.

    Article  PubMed  CAS  Google Scholar 

  70. Frank O, Giehl M, Zheng C, Hehlmann R, Leib-Mosch C, Seifarth W. Human endogenous retrovirus expression profiles in samples from brains of patients with schizophrenia and bipolar disorder. J Virol. 2005;79(17):10890–901.

    Article  PubMed  CAS  Google Scholar 

  71. Weis S, Llenos IC, Sabunciyan S, et al. Reduced expression of human endogenous retrovirus (HERV)-W GAG protein in the cingulate gyrus and hippocampus in schizophrenia, bipolar disorder, and depression. J Neural Transm. 2007;114(5):645–55.

    Article  PubMed  CAS  Google Scholar 

  72. Perron H, Mekaoui L, Bernard C, Veas F, Stefas I, Leboyer M. Endogenous retrovirus type W GAG and envelope protein antigenemia in serum of schizophrenic patients. Biol Psychiatry. 2008;64(12):1019–23.

    Article  PubMed  CAS  Google Scholar 

  73. • Perron H, Hamdani N, Faucard R, et al. Molecular characteristics of Human Endogenous Retrovirus type-W (HERV-W) in schizophrenia and bipolar disorder. Transl Psychiatry. 2012. doi:10.1038/tp.2012.125. The only study involving the HERV in bipolar disorder.

    PubMed  Google Scholar 

  74. Antony JM, van Marle G, Opii W, Butterfield DA, Mallet F, Yong VW, et al. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci. 2004;7(10):1088–95.

    Article  PubMed  CAS  Google Scholar 

  75. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157(5):683–94.

    Article  PubMed  CAS  Google Scholar 

  76. Kronfol Z, LeMay L, Nair M, Kluger M. Electroconvulsive therapy increases plasma levels of interleukin-6. Ann NY Acad Sci. 1990;594:463–5.

    Article  Google Scholar 

  77. Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord. 2004;82(2):309–13.

    Article  PubMed  CAS  Google Scholar 

  78. Maes M, Calabrese J, Jayathilake K, Meltzer HY. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Res. 1997;71(2):67–76.

    Article  PubMed  CAS  Google Scholar 

  79. Rapaport MH. Immune parameters in euthymic bipolar patients and normal volunteers. J Affect Disord. 1994;32(3):149–56.

    Article  PubMed  CAS  Google Scholar 

  80. Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology. 1997;35(3):123–7.

    Article  PubMed  CAS  Google Scholar 

  81. Bubak-Satora M, Skowron-Cendrzak A, Kubera M. The effect of lithium chloride treatment on cell-mediated immunity in mice. Folia Biol (Krakow). 1991;39(1–4):21–4.

    CAS  Google Scholar 

  82. Krause I, Cohen J, Blank M, et al. Distribution of two common idiotypes of anticardiolipin antibodies in sera of patients with primary antiphospholipid syndrome, systemic lupus erythematosus and monoclonal gammopathies. Lupus. 1992;1(2):91–6.

    Article  PubMed  CAS  Google Scholar 

  83. Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003;62(3):237–44.

    Article  PubMed  Google Scholar 

  84. Vale S, Espejel MA, Dominguez JC. Amantadine in depression. Lancet. 1971;2(7721):437.

    Article  PubMed  CAS  Google Scholar 

  85. Bode L, Durrwald R, Rantam FA, et al. First isolates of infectious human Borna disease virus from patients with mood disorders. Mol Psychiatry. 1996;1(3):200–12.

    PubMed  CAS  Google Scholar 

  86. Dietrich DE, Bode L, Spannhuth CW, et al. Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord. 2000;2(1):65–70.

    Article  PubMed  CAS  Google Scholar 

  87. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry. 1999;32(2):47–55.

    Article  PubMed  CAS  Google Scholar 

  88. Muller N, Schwarz MJ, Dehning S, Douhe A, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680–4.

    Article  PubMed  CAS  Google Scholar 

  89. Casolini P, Catalani A, Zuena AR, Angelucci L. Inhibition of COX-2 reduce the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res. 2002;68(3):337–43.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by INSERM (UMRS 940 and U955), assistante Publique des Hôpitaux de Paris, Agence Nationale de la Recherche (programmeANR-MNP2008 - VIP project) and fondaMental foundation.

Compliance with Ethics Guideline

ᅟ

Conflict of Interest

Nora Hamdani, Raphael Doukhan, Ozlem Kurtlucan, Ryad Tamouza, and Marion Leboyer declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Universite Paris Est, Faculte de medecine, Creteil, 94000, France

    Nora Hamdani & Marion Leboyer

  2. AP-HP, Hopital H. Mondor, A. Chenevier, Pole de psychiatrie, Creteil, 94000, France

    Nora Hamdani, Raphael Doukhan, Ozlem Kurtlucan & Marion Leboyer

  3. INSERM, U955, Equipe Psychiatrie Genetique, Creteil, 94000, France

    Nora Hamdani & Marion Leboyer

  4. INSERM, U940, Immunologie et Histocompatibilite, Hopital Saint-Louis, Paris, 75010, France

    Ryad Tamouza

  5. Fondation FondaMental, Creteil, 94000, France

    Nora Hamdani, Ryad Tamouza & Marion Leboyer

  6. Pole de Psychiatrie, Hôpital A Chenevier, 40 rue de Mesly, Créteil, 94000, France

    Nora Hamdani

Authors
  1. Nora Hamdani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raphael Doukhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ozlem Kurtlucan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryad Tamouza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marion Leboyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nora Hamdani.

Additional information

This article is part of the Topical Collection on Bipolar Disorders

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamdani, N., Doukhan, R., Kurtlucan, O. et al. Immunity, Inflammation, and Bipolar Disorder: Diagnostic and Therapeutic Implications. Curr Psychiatry Rep 15, 387 (2013). https://doi.org/10.1007/s11920-013-0387-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-013-0387-y

Keywords

Search

Navigation